Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk is cutting the price of its weight-loss ... The injectable medication's price is the same for five dosages ranging from 0.25 to 2.4 milligrams and will be shipped directly to ...
Novo Nordisk is cutting the cost of its blockbuster ... This includes 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg dose strengths. The list price of the drug before insurance and certain rebates ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback